Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

COVID-19 Patients Show Liver Injury Months After Infection


CHICAGO, Dec. 1, 2022 /PRNewswire/ -- COVID-19 infection is associated with increased liver stiffness, a sign of possible long-term liver injury, according to the results of a new study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

"Our study is part of emerging evidence that COVID-19 infection may lead to liver injury that lasts well after the acute illness," said Firouzeh Heidari, M.D., a post-doctorate research fellow at Massachusetts General Hospital in Boston.

Liver stiffness is a marker of liver damage, such as inflammation or fibrosis. Fibrosis is the buildup of scar tissue in the liver. Over time, healthy liver tissue diminishes, and the liver can no longer function properly. Progressive fibrosis can lead to liver cancer and liver failure.

In the retrospective study, the researchers compared liver stiffness of patients with a history of COVID-19 infection to two control groups. All patients underwent ultrasound shear wave elastography between 2019 and 2022 at Massachusetts General Hospital. Shear wave elastography is a specialized technique that uses sound waves to measure the stiffness of tissue.

The patients were categorized into one of three groups based on when they underwent elastography and whether they tested positive for COVID-19. The COVID-19 positive group contained 31 patients who had a positive COVID-19 PCR test result at least 12 weeks before the elastography exam. The pandemic control group consisted of a random sample of 50 patients who underwent elastography during the COVID-19 pandemic and had a history of only negative COVID-19 PCR test results. The pre-pandemic control group consisted of a random sample of 50 patients who underwent an elastography exam prior to the COVID-19 pandemic.

The mean age was 53.1 years for the COVID-positive patients, 55.2 years for the pandemic control group and 58.2 years for the pre-pandemic control group. Of the total cohort, 67 were women. In the COVID-positive group, elastography exams were performed an average of 44 weeks after a positive PCR test result.

After controlling for age, sex and time period, a statistical analysis of the elastography results revealed that COVID-positive patients had a statistically significant higher liver stiffness than the control patients.

COVID-positive patients had a higher median live stiffness (7.68 kPa) than pandemic control patients (5.99 kPa).

Unexpectedly, the pre-pandemic control group also had a higher median stiffness (7.01) compared to pandemic control group. The reason for this finding is not yet understood but is believed to be a result of changing referral patterns during the pandemic. Additionally, patients referred for elastography before the pandemic were noted to be older than patients referred after the start of the pandemic.

"We don't yet know if elevated liver stiffness observed after COVID-19 infection will lead to adverse patient outcomes," Dr. Heidari said. "We are currently investigating whether the severity of acute COVID-related symptoms is predictive of long-term liver injury severity. We hope to enrich our existing database with additional patient data and a broader scope of co-variates to better understand the post-acute effects of COVID-19 within the liver."

Co-authors are Theodore Pierce, M.D., Anthony Samir, M.D., M.P.H., Arinc Ozturk, M.D., Madhangi Parameswaran, M.B.B.S., M.Res., Marian Martin, M.D., M.P.H., and Hannah Edenbaum, M.S.

Note: Copies of RSNA 2022 news releases and electronic images will be available online at RSNA.org/press22.

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on elastography, visit RadiologyInfo.org.

SOURCE Radiological Society of North America (RSNA)


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: